Status:
COMPLETED
Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2
Lead Sponsor:
University Hospital, Lille
Conditions:
Familial Partial Lipodystrophy Type 2
Eligibility:
All Genders
15+ years
Brief Summary
Familial partial lipodystrophic syndromes are characterized by an increase in visceral adipose tissue and an atrophy of subcutaneous adipose tissue. They are associated with a severe metabolic syndrom...
Eligibility Criteria
Inclusion
- Familia partial lipodystrophy type 2 (FPL2) with the R482 codon mutation of the LMNA gene
- Social insured
- Ability to give consent
Exclusion
- urinary incontinence or inability to collect urine for 24 hours
- moderate and severe kidney insufficiency
- hepatic insufficiency
- history of hypercortisolism or adrenal insufficiency
- treatment interfering with the cortisol metabolism: taking oral or inhaled glucocorticoids within the last 6 months
- pregnant and lactating woman.
Key Trial Info
Start Date :
April 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 9 2023
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04845165
Start Date
April 19 2022
End Date
November 9 2023
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Claude Huriez
Lille, France, 59037